United States - English - NLM (National Library of Medicine)

guardian drug company - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk), diatrizoate sodium (unii: v5403h8vg7) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine and diatrizoate sodium solution is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). the preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. diatrizoate meglumine and diatrizoate sodium solution may also be used as an adjunct to contrast enhancement is computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology. do not administer to patients with a known hypersensitivity to diatrizoate meglumine and diatrizoate sodium solution or any of its components.

United States - English - NLM (National Library of Medicine)

bracco diagnostics inc - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk), diatrizoate sodium (unii: v5403h8vg7) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine 660 mg in 1 ml - gastrografin (diatrizoate meglumine and diatrizoate sodium solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). the preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology. do not administer to patients with a known hypersensitivity to gastrografin or any of its components.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk), diatrizoate sodium (unii: v5403h8vg7) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine and diatrizoate sodium solution is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). the preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. diatrizoate meglumine and diatrizoate sodium solution may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology. do not administer to patients with a known hypersensitivity to diatrizoate meglumine and diatrizoate sodium solution or any of its components.

United States - English - NLM (National Library of Medicine)

liebel-flarsheim company llc - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk), diatrizoate sodium (unii: v5403h8vg7) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine 600 mg in 1 ml - md-gastroview (diatrizoate meglumine and diatrizoate sodium solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). the preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. md-gastroview may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous admin­istration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology. do not administer to patients with a known hypersensitivity to md-gastroview or any of its components.

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk) - injection, solution - 60 g in 100 ml - hypaque meglumine 60 percent is indicated for excretory urography; cerebral angiography; peripheral arteriography; venography; operative, t-tube, or percutaneous transhepatic cholangiography; splenoportography; arthrography; discography; and contrast enhancement of computed tomographic head imaging. diatrizoate salts are used in small, medium, and large dose urography (see dosage and administration-excretory urography). visualization of the urinary tract can be achieved by either direct intravenous bolus injection, intravenous drip infusion, or incidentally following intra-arterial procedures. visualization of the urinary tract is delayed in infants less than 1 month old, and in patients with urinary tract obstruction (see clinical pharmacology). injectable radiopaque contrast media may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. radiopaque diagnostic agents may be useful to investigate the presence and extent of certain malignancie

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoate - unii:), diatrizoate sodium (unii: v5403h8vg7) (diatrizoate - unii:) - injection, solution - 660 mg in 1 ml - hypaque-76 is indicated for excretory urography, aortography, angiocardiography (ventriculography, pulmonary angiography, selective coronary arteriography), peripheral angiography (peripheral arteriography and peripheral venography), intravenous digital arteriography, contrast enhancement of computed tomographic head imaging, contrast enhancement of computed tomographic body imaging, selective renal arteriography, selective visceral arteriography, central venography, and renal venography. in addition to the following generalcontraindications, warnings, precautions, and adverse reactions, there are additional listings in these categories under the particular procedures. hypaque-76 has no absolute contraindications in its recommended uses (see general warnings and precautions). do not use hypaque-76 for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. even a small amount in the subarachnoid space may produce convulsions and result in fatality. (see

United States - English - NLM (National Library of Medicine)

liebel-flarsheim company llc - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine 660 mg in 1 ml

United States - English - NLM (National Library of Medicine)

e-z-em canada inc - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine 660 mg in 1 ml

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate sodium (unii: v5403h8vg7) (diatrizoic acid - unii:5uvc90j1lk) - injection, solution - 500 mg in 1 ml - hypaque sodium 50 percent is indicated for excretory urography, cerebral and peripheral angiography, aortography, intraosseous venography, direct cholangiography, hysterosalpingography, splenoportography, and contrast enhancement of computed tomographic head imaging. diatrizoate salts are used in small, medium, and large dose urography (see dosage and administration—excretory urography). visualization of the urinary tract can be achieved by either direct intravenous bolus injection, intravenous drip infusion, or incidentally following intra-arterial procedures.visualization of the urinary tract is delayed in infants less than 1 month old, and in patients with urinary tract obstruction (see clinical pharmacology). injectable radiopaque contrast media may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. radiopaque diagnostic agents may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malig

Kenya - English - Pharmacy and Poisons Board

bayer pharma ag bayer pharma ag 13342 berlin germany - sodium diatrizoate / meglumine diatrizoate - solution for injection - 1 ml urografin 76 % contains 0.1 g sodium… - contrast media - iodinated x-raycontrast media: